Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection | Zendy

Roberto L. Patron | Zendy; Carlos Hartmann | Zendy; Sorcha Allen | Zendy; Cheryl L. Griesbach | Zendy; Heidi E. Kosiorek | Zendy; John K. DiBaise | Zendy; Robert Orenstein | Zendy

Open Access

Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection

Author(s) -

Roberto L. Patron,

Carlos Hartmann,

Sorcha Allen,

Cheryl L. Griesbach,

Heidi E. Kosiorek,

John K. DiBaise,

Robert Orenstein

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix511

Subject(s) - clostridium difficile , medicine , odds ratio , vancomycin , fecal bacteriotherapy , confidence interval , risk factor , transplantation , cohort study , surgery , gastroenterology , antibiotics , microbiology and biotechnology , genetics , bacteria , biology , staphylococcus aureus

We retrospectively analyzed a cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota transplantation (FMT) at a tertiary referral center between 2011 and 2014 to determine risk factors for FMT failure. In a multivariate analysis, failure to use an oral vancomycin taper preceding FMT was associated with a significant risk of FMT failure (odds ratio, 0.15; 95% confidence interval, .007-.40).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research